COHERUS BIOSCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.955 USD | -3.22% |
|
-2.75% | -41.59% |
Chart calendar Coherus BioSciences, Inc.
3701725.ho74bFEH2O2aZ4NQ7ilkZ_ksnoRczWL2b-y9JT4kWNc.9unKCRtPk6fKAew_o0wiC6kd7allozGPGZaESXByM4bt5sw-fGWQ2KMAuw~024e3fb3a532a282741d40f3ab9c6458
Upcoming events on Coherus BioSciences, Inc.
Past events on Coherus BioSciences, Inc.
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract: 1364/15 |
| 2024-03-13 05:00 pm | Q4 2023 Earnings Call |
| 2024-03-13 04:01 pm | Q4 2023 Earnings Release |
| 2024-01-22 08:30 am | Business Update Call |
| 2024-01-19 03:30 pm | American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Abstract number: 470 |
| 2024-01-10 12:45 pm | JPMorgan Healthcare Conference |
| 2023-12-07 06:00 am | European Society for Medical Oncology Immuno Oncology Congress |
| 2023-11-30 12:30 pm | Evercore ISI HealthCONx Conference |
| 2023-11-28 | GCFF Virtual Healthcare Conference |
| 2023-11-09 11:30 am | UBS BioPharma Conference |
| 2023-11-07 | Truist Securities Healthcare Conference |
| 2023-11-06 05:00 pm | Q3 2023 Earnings Call |
| 2023-11-06 04:07 pm | Q3 2023 Earnings Release |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract #1354 |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract #468 |
| 2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract #1351 |
| 2023-10-27 04:30 pm | LOQTORZI FDA Approval Call |
| 2023-09-12 01:30 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-06 | Wells Fargo Healthcare Conference |
| 2023-09-06 03:30 pm | Citi BioPharma Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 356 356 0.08% | 476 480 -0.92% | 327 336 -2.76% | 211 214 -1.19% | 257 255 0.71% | 262 |
|
EBITDA Million USD | Released Forecast Spread | 111 128 -13.26% | 159 176 -9.64% | -260 -104 -150.39% | -253 -237 -6.65% | -148 -138 -7.58% | -5,21 |
|
EBIT Million USD | Released Forecast Spread | 108 122 -11.32% | 156 169 -7.76% | -264 -161 -63.63% | -257 -255 -0.74% | -203 -149 -36.4% | -92,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 92,8 107 -13.18% | 136 144 -5.88% | -287 -272 -5.42% | -292 -290 -0.61% | -238 -192 -24.29% | -60,9 |
|
Net income Million USD | Released Forecast Spread | 89,8 106 -14.99% | 132 148 -10.48% | -287 -207 -38.43% | -292 -299 2.52% | -238 -178 -34% | -69,4 |
|
EPS USD | Released Forecast Spread | 1,23 1,37 -10.18% | 1,62 1,66 -2.49% | -3,81 -3,62 -5.35% | -3,76 -3,95 4.71% | -2,53 -2,01 -25.62% | -0,55 |
| Announcement Date | 27/02/20 | 24/02/21 | 17/02/22 | 06/03/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 73,4 82,6 -11.19% | 60,1 70,5 -14.78% | 60,2 61,4 -2.1% | 45,4 56,4 -19.41% | 45,4 48,0 -5.45% | 32,4 46,3 -29.93% | 58,7 50,5 16.33% | 74,6 81,8 -8.87% | 91,5 90,4 1.21% | 83,7 | 53,7 | 59,0 | 64,1 | 65,0 |
|
EBITDA Million USD | Released Forecast Spread | -38,7 -56,0 30.87% | -80,2 -35,0 -129.02% | -43,1 -49,1 12.1% | -79,5 -51,4 -54.58% | -50,4 -74,6 32.35% | -50,6 -37,5 -34.73% | -23,6 -36,8 35.89% | -18,3 -21,7 15.72% | -57,4 -14,0 -310.14% | 2,00 | -1,00 | 8,00 | 15,0 | |
|
EBIT Million USD | Released Forecast Spread | -39,5 -30,9 -28.11% | -80,9 -56,6 -43.03% | -44,0 -59,0 25.41% | -80,4 -55,3 -45.53% | -51,5 -65,2 21.06% | -67,7 -62,8 -7.93% | -34,5 -44,8 22.87% | -32,0 -8,88 -260.35% | -68,9 -21,5 -220.1% | -27,6 | -33,1 | -19,0 | -13,0 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -45,7 -31,0 -47.62% | -96,1 -81,3 -18.12% | -50,2 -69,2 27.56% | -86,7 -56,1 -54.44% | -58,9 -57,1 -3.1% | -75,7 -57,0 -32.86% | -42,9 -54,7 21.69% | -40,0 -31,7 -26.31% | -79,7 -33,1 -140.92% | 11,5 | -35,6 | -21,4 | -15,5 | |
|
Net income Million USD | Released Forecast Spread | -45,7 -28,7 -59.28% | -96,1 -81,3 -18.12% | -50,2 -69,2 27.56% | -86,7 -56,1 -54.44% | -58,9 -80,0 26.42% | -75,7 -59,9 -26.53% | -42,9 -53,2 19.45% | -39,6 -25,5 -55.26% | -79,7 -19,2 -314.72% | 10,1 | -35,6 | -21,4 | -15,5 | |
|
EPS USD | Released Forecast Spread | -0,60 -0,51 -16.96% | -1,24 -0,80 -55.06% | -0,65 -0,86 24.12% | -1,11 -0,80 -39.28% | -0,76 -0,98 22.52% | -0,96 -0,83 -15.86% | -0,49 -0,65 25.12% | -0,41 -0,31 -31.42% | -0,71 -0,20 -250.79% | 0,03 | -0,26 | -0,14 | -0,08 | |
| Announcement Date | 17/02/22 | 05/05/22 | 04/08/22 | 08/11/22 | 06/03/23 | 08/05/23 | 02/08/23 | 06/11/23 | 13/03/24 | - | - | - | - | - |
More events
Past sector events for Coherus BioSciences, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CHRS Stock
- Calendar Coherus BioSciences, Inc.
